In Brief: Endovascular Technologies, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Endovascular Technologies, Inc.: Expects to begin prospective Phase II clinical trials of its Aortoiliac EGS system, which is designed to treat aneurysms in which one iliac artery is unsuitable for endovascular attachment of an implant. The planned 20-site study, for which an investigational device exemption application recently was approved by FDA, will compare mortality, complications, and length of hospital stay among patients treated with the Aortoiliac EGS and those receiving conventional treatment...
You may also be interested in...
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.